XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net revenues $ 4,332 $ 3,850 $ 12,315 $ 11,389
Cost of sales 2,183 1,999 6,372 6,159
Gross profit 2,148 1,851 5,943 5,230
Research and development expenses 240 253 751 726
Selling and marketing expenses 626 576 1,891 1,726
General and administrative expenses 298 268 859 870
Intangible assets impairments 28 47 169 289
Goodwill impairment 600 0 1,000 700
Other assets impairments, restructuring and other items [1] (23) 57 931 276
Legal settlements and loss contingencies 450 314 638 1,009
Other loss (income) (21) (9) (22) (43)
Operating income (loss) [1] (51) 344 (274) (323)
Financial expenses, net 272 280 763 808
Income (loss) before income taxes [1] (324) 64 (1,037) (1,131)
Income taxes (benefit) 69 (12) 648 (48)
Share in (profits) losses of associated companies, net (3)   (1) (1)
Net income (loss) (390) 77 (1,684) (1,082)
Net income (loss) attributable to non-controlling interests 47 8 (262) (60)
Net income (loss) attributable to Teva $ (437) $ 69 $ (1,422) $ (1,022)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.39) $ 0.06 $ (1.26) $ (0.91)
Diluted $ (0.39) $ 0.06 $ (1.26) $ (0.91)
Weighted average number of shares (in millions):        
Basic 1,133 1,121 1,130 1,119
Diluted 1,133 1,135 1,130 1,119
[1] The data presented for the prior period have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information see note 1c.